Eli Lilly and Company (NYSE:LLY) Shares Sold by Central Bank & Trust Co.

Central Bank & Trust Co. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.7% in the third quarter, HoldingsChannel reports. The institutional investor owned 2,254 shares of the company’s stock after selling 298 shares during the quarter. Central Bank & Trust Co.’s holdings in Eli Lilly and Company were worth $1,997,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of LLY. China Universal Asset Management Co. Ltd. raised its holdings in shares of Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after acquiring an additional 1,620 shares during the period. Quent Capital LLC lifted its holdings in shares of Eli Lilly and Company by 5.3% in the first quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock valued at $3,846,000 after purchasing an additional 249 shares in the last quarter. Mutual Advisors LLC boosted its position in shares of Eli Lilly and Company by 404.8% in the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock worth $48,699,000 after buying an additional 50,197 shares during the period. Whittier Trust Co. grew its holdings in shares of Eli Lilly and Company by 52.2% during the first quarter. Whittier Trust Co. now owns 75,487 shares of the company’s stock valued at $58,725,000 after buying an additional 25,877 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in Eli Lilly and Company by 155.1% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 19,745 shares of the company’s stock worth $15,361,000 after acquiring an additional 12,004 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.6 %

Shares of Eli Lilly and Company stock opened at $806.14 on Tuesday. Eli Lilly and Company has a 52-week low of $561.65 and a 52-week high of $972.53. The firm has a market capitalization of $765.28 billion, a PE ratio of 87.15, a price-to-earnings-growth ratio of 3.09 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The company’s fifty day moving average price is $908.15 and its two-hundred day moving average price is $867.39.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the previous year, the firm earned $0.10 EPS. The business’s revenue was up 20.4% compared to the same quarter last year. On average, analysts expect that Eli Lilly and Company will post 13.23 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.65%. Eli Lilly and Company’s payout ratio is presently 56.22%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on LLY shares. Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Citigroup increased their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Finally, Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,008.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.